Replies to post #58666 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

So, it appears to be "spin"?

First that they say attacking other than M-1 has previously caused side effects, then they say that 2-73 attacks other than M-1, concluding without a clear logical argument that this "lack of selectivity" will cause side effects.

As far as today’s tie-up goes, Allergan will clearly have studied the muscarinic space before settling on Heptares, which Mr Weir said had the most advanced project. Anavex’s phase II asset ANAVEX 2-73 is a muscarinic agonist, but also agonises the sigma-1 receptor, which Mr Weir said meant that it lacked HTL18318’s selectivity.

http://epvantage.com/Universal/View.aspx?type=Story&id=632030&isEPVantage=yes

Is this a reasonable interpretation of that press release?